Caracterização dos acometimentos relacionados à morbimortalidade na esclerose sistêmica
DOI:
https://doi.org/10.33233/fb.v17i1.29Abstract
Introdução: A esclerose sistêmica é uma doença difusa do tecido conectivo de natureza autoimune com etiologia desconhecida, caracterizada primariamente pelo aumento de deposição de colágeno na matriz extracelular. Objetivo: Caracterização dos acometimentos relacionados à morbimortalidade na esclerose sistêmica por meio da revisão de literatura. Métodos: Elaborado a partir de revisão literária de artigos publicados entre os anos de 1993 e 2013 indexados nas línguas portuguesa e inglesa, que utilizou como fonte de pesquisa as bases de dados Scielo, Bireme, Pedro e Pubmed nacionais e internacionais, por meio de método de mensuração baseada na quantidade de citações. Resultados: O estudo revelou como características da esclerose sistêmica, os seguintes acometimentos: fenômeno de Raynaud, úlceras cutâneas, complicações esofágicas, insuficiência renal, hipertensão pulmonar e doença intersticial pulmonar. O maior percentual (47,63%) de acometimento refere-se à doença intersticial pulmonar, acompanhada por um percentual (45,16%) atribuído aos episódios de fenoÌ‚meno de Raynaud. Conclusão: Conclui-se, portanto, que, por meio da análise de citações dos acometimentos da esclerose sistêmica, o que prevalece principalmente são as manifestações pulmonares como causa importante de morbimortalidade neste tipo de paciente.
Palavras-chave: esclerose sistêmica, inflamação, morbidade, mortalidade, manifestações cutâneas.
References
Geirsson AJ, Steinsson K, Guthmundsson S, Sigurthsson V. Systemic sclerosis in Iceland. A nationwide epidemiological study. Ann Rheum Dis 1994;53:502-5.
Rossa AD, Valentini G, Bombardieri S. European multicenter study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 2001;60:585-91.
Tan FK. Systemic sclerosis: the susceptible host (genetics and environment). Rheum Dis Clin North Am 2003;29(2):211-37.
Kahan A, Menkes CJ, Amor B. Defective Epstein-Barr virus specific suppressor T cell function in progressive systemic sclerosis. Ann Rheum Dis 1986;45(7):553-60.
Zakrzewska K, Corcioli F, Carlsen KM, Giuggioli D, Fanci R, Rinieri A. Human parvovirus B19 (B19V) infection in systemic sclerosis patients. Intervirology 2009;52(5):279-82.
Steen VD, Medsger Junior TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43(11):2437-44.
Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005;52(2):592-600.
Minai OA, Dweik RA, Arroliga AC. Manifestations of scleroderma pulmonary disease. Clin Chest Med 1998;19(4):713-31.
Sahhar J, Littlejohn G, Conron M. Fibrosing alveolitis in systemic sclerosis: the need for early screening and treatment. Intern Med J 2004;34:626-38.
Del Rosso A, Boldrini M, D’Agostino D, Placidi GP, Scarpato A, Pignone A. Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers. Arthritis Rheum 2004;51(3):475-81.
Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006;2(3):134-44.
Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002;81(2):139-53.
Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer-Green G. The evolution of Raynaud,s phenomenon: a long term prospective study. J Rheumatol 1995;22:2226-32.
Weinstein WM, Kadell BM. The gastrointestinal tract in systemic sclerosis. In: Clements PJ, Furst DE, ed. Systemic sclerosis. 2a ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p.293-308.
Fitzgerald RC, Triadafilopoulos G. Esophageal manifestations of rheumatic diseases. Semin Arthritis Rheum 1997;26:641-56.
Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 1996;22:861-78.
De Marco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46:2983-9.
Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 1979;119:471-503.
Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults. N Engl J Med 2000;342:235-49.
Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003;29:371-90.
Marques Neto JF, Sampaio-Barros PD. Esclerose SisteÌ‚mica. In: Moreira C, Carvalho MAP, eds. Reumatologia diagnoÌstico e tratamento. 2a ed. Belo Horizonte: Medsi; 2001; p.465-88.
Denton CP, Black CM. Pulmonary vascular involvement in systemic sclerosis. In: Clements PJ, Furst DE, eds. Systemic sclerosis. 2a ed. Philadelphia: Lippincott Williams & Wilkins; 2004; p.184-94.
Denton CP, Cailes JB, Phillipis GD, Wells AU, Black CM, Du Bois RM. Comparison of doppler echocardiography and right heart catheterization in systemic sclerosis. Br J Rheumatol 1997;36:239-43.
Jezler S, Santiago MB, Lessa T, Araujo Neto C, Braga H, Cruz AA. Comprometimento do interstÃcio pulmonar em portadores de Esclerose Sistêmica Progressiva (ESP): estudo de uma série de 58 casos. J Bras Pneumol 2005;31(4)300-6.
Steen VD, Medsger Junior TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43(11):2437-44.
Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003;62:97-9.
White B. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2003;29:371-90.
Steen VD, Conte C, Owens GR, Medsger Junior TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
Downloads
Published
Issue
Section
License
Authors are authorized for non-exclusive distribution of the version of the work published in this journal (eg, publishing in an institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
